Stockscreener 앱 받기
1.545
5.79%
-0.095
전일 마감가:
$1.64
열려 있는:
$1.6
하루 거래량:
9,050
Relative Volume:
0.47
시가총액:
$16.58M
수익:
-
순이익/손실:
$-17.93M
주가수익비율:
-0.8729
EPS:
-1.77
순현금흐름:
$-14.28M
1주 성능:
-5.21%
1개월 성능:
+0.06%
6개월 성능:
-19.03%
1년 성능:
-40.81%
1일 변동 폭
$1.54
$1.6115
1주일 범위
$1.54
$1.7099
52주 변동 폭
$1.12
$3.26
Cocrystal Pharma Inc Stock (COCP) Company Profile
명칭
Cocrystal Pharma Inc
전화
(786) 459-1831
주소
19805 N. CREEK PARKWAY, BOTHELL, WA
COCP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.54 | 16.58M | 0 | -17.93M | -14.28M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.21 | 113.97B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
519.77 | 52.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
303.27 | 40.16B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
581.40 | 35.45B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
272.10 | 27.80B | 3.81B | -644.79M | -669.77M | -6.24 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-07-08 | 개시 | H.C. Wainwright | Buy |
Cocrystal Pharma Inc 주식(COCP)의 최신 뉴스
Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference - The Globe and Mail
Cocrystal Pharma’s CDI-988 Featured at Military Symposium - TipRanks
Military Defense Selects Revolutionary Norovirus Drug: First-Ever Dual Prevention and Treatment Shows Promise - Stock Titan
Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 Vaccines - Investing News Network
What is Zacks Small Cap’s Forecast for COCP FY2025 Earnings? - Defense World
Influenza Pipeline Appears Robust With 120+ Key Pharma - openPR.com
Cocrystal Pharma (COCP) Reports Promising Results with Influenza Inhibitor | COCP Stock News - GuruFocus
Cocrystal Pharma, Inc.'S Investigational Drug Candidate Cc-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5n1 Avian Influenza Strain - marketscreener.com
Cocrystal Pharma’s CC-42344 Shows Strong Antiviral Potency - TipRanks
Cocrystal’s flu drug shows promise against H5N1 strain - Investing.com Australia
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
Cocrystal Pharma's CC-42344 Shows Strong Antiviral Potency Against 2024 H5n1 Avian Influenza Strain - marketscreener.com
Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain - The Manila Times
ARB IOT Group Limited Announces 1-for-15 Reverse Share Split - The Manila Times
Upexi Partners with Crypto-Native Marketing and Design Firm, GMI Digital, to Drive Solana-Focused Strategy - The Manila Times
Breakthrough: New Drug Crushes Tamiflu Efficacy in Fighting Dangerous Bird Flu Strain, Lab Study Shows - Stock Titan
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - The Manila Times
Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference - The Manila Times
Cocrystal Pharma Announces Exclusive Investor Access: Live Q&A and One-on-One Meetings at Noble Conference - Stock Titan
COCP: Topline Results for High-Dose Cohort from Phase 1 Trial of CDI-988 Expected in 2Q25… - MSN
What is Noble Financial’s Estimate for COCP Q2 Earnings? - Defense World
Cocrystal Pharma Reports First Quarter 2025 Financial Results an - GuruFocus
Cocrystal Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cocrystal Pharma (COCP) Advances CDI-988 for Norovirus Treatment - GuruFocus
Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - The Manila Times
Cocrystal Pharma (COCP) Advances CDI-988 for Norovirus Treatment | COCP Stock News - GuruFocus
Breakthrough: Cocrystal's Novel Antiviral CDI-988 Demonstrates Superior Activity Against All Major Norovirus Variants - Stock Titan
Cocrystal Pharma (COCP) Projected to Post Earnings on Monday - Defense World
Cocrystal Pharma's Novel Norovirus Antiviral to Be Presented at Department of Defense Medical Conference - marketscreener.com
Norovirus Infection Pipeline: 8+ Leading Companies Advancing - openPR.com
Cocrystal Pharma (COCP) Advances Norovirus Drug Candidate CDI-98 - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Hepatitis C Virus Infection Pipeline: 20+ Leading Companies - openPR.com
Cocrystal Pharma (NASDAQ:COCP) Stock Price Up 3.3% – Here’s Why - Defense World
Cocrystal Pharma Advances Norovirus Antiviral Candidate CDI-988 - TipRanks
Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants - The Manila Times
First-Ever Norovirus Treatment Tackles Dominant 2024 Variants: $60B Market Opportunity - Stock Titan
Cocrystal Pharma Presents to Investment Community - TipRanks
Aytu BioPharma Stock Price, Quotes and Forecasts - Benzinga
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference - The Manila Times
Cocrystal Pharma CEO to Reveal Latest Developments at Elite Northwest Biotech Summit - Stock Titan
Addex Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ADXN - Benzinga
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama® - MarketScreener
Strategic Patent Filing Could Transform VTAMA's $233B Market Potential - Stock Titan
OTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst at Zacks SCR - Zacks Small Cap Research
Cocrystal Pharma Approves 2025 Equity Incentive Plan - TipRanks
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA - openPR.com
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
COCRYSTAL PHARMA Earnings Preview: Recent $COCP Insider Trading, Hedge Fund Activity, and More - Nasdaq
Q1 Earnings Forecast for COCP Issued By Zacks Small Cap - Defense World
COCP stock touches 52-week low at $1.35 amid market fluctuations By Investing.com - Investing.com South Africa
Cocrystal Pharma Inc (COCP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.06%
0.26%
자본화:
|
볼륨(24시간):